Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

This study looks at real-world outcomes of pembrolizumab (an immunotherapy drug) treatment in Black/African American patients with advanced non-small cell lung cancer (NSCLC) — a group historically underrepresented in clinical trials — to understand whether results differ from other populations. **You may be eligible if...** - You are 18 or older - You self-identify as Black or African American - You have advanced or metastatic NSCLC (confirmed by biopsy) - You have not received prior chemotherapy or immunotherapy for your advanced lung cancer - Your tumor does not have EGFR, ALK, or ROS1 mutations - You have PDL1 test results available - You are in reasonably good physical condition (ECOG 0–2) **You may NOT be eligible if...** - You have active autoimmune disease requiring systemic treatment - You have active or untreated brain metastases - You have known interstitial lung disease or prior pneumonitis requiring steroids - You are pregnant or breastfeeding - You received a live vaccine within the past 30 days Talk to your doctor to see if this trial is right for you.